GCTK — GlucoTrack Share Price
Last trade - 00:00- $7.23m
- $5.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 31.91 | ||
| Price to Tang. Book | 31.91 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1405.61% | ||
| Return on Equity | -4515.76% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.21 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.
Directors
- Paul Goode PRE (53)
- Jolie Kahn CFO (56)
- Shalom Shushan CTO (49)
- Erez Ben-Zvi VPR (42)
- Luis Malave DRC
- Andrew Sycoff DRC (54)
- Allen Danzig IND (65)
- Robert Fischell IND (92)
- Shimon Rapps IND (41)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 18th, 2010
- Public Since
- April 9th, 2013
- No. of Shareholders
- 341
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 5,478,599
- Address
- 301 Rte 17 North, Ste. 800, RUTHERFORD, 07070
- Web
- Phone
- +1 2018427715
- Auditors
- Fahn, Kanne & Co.
Upcoming Events for GCTK
Similar to GCTK
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 20:53 UTC, shares in GlucoTrack are trading at $2.19. This share price information is delayed by 15 minutes.
Shares in GlucoTrack last closed at $2.19 and the price had moved by +7.62% over the past 365 days. In terms of relative price strength the GlucoTrack share price has underperformed the S&P500 Index by -14.37% over the past year.
There is no consensus recommendation for this security.
GlucoTrack does not currently pay a dividend.
GlucoTrack does not currently pay a dividend.
GlucoTrack does not currently pay a dividend.
To buy shares in GlucoTrack you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.19, shares in GlucoTrack had a market capitalisation of $12.00m.
Here are the trading details for GlucoTrack:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GCTK
Based on an overall assessment of its quality, value and momentum GlucoTrack is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GlucoTrack. Over the past six months, its share price has outperformed the S&P500 Index by +37.66%.
As of the last closing price of $2.19, shares in GlucoTrack were trading +36.43% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The GlucoTrack PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
GlucoTrack's management team is headed by:
- Paul Goode - PRE
- Jolie Kahn - CFO
- Shalom Shushan - CTO
- Erez Ben-Zvi - VPR
- Luis Malave - DRC
- Andrew Sycoff - DRC
- Allen Danzig - IND
- Robert Fischell - IND
- Shimon Rapps - IND